Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Stock Regains 7 Percent of Value Lost After Positive Biomarker Discovery News

NEW YORK, May 26 (GenomeWeb News) - Shares in Ciphergen this afternoon regained the roughly 7 percent they lost yesterday despite news that the company discovered biomarkers that may predict the recurrence of prostate cancer.

Ciphergen's stock was trading up at $1.82 in mid-afternoon trading today -- right around where they opened on Wednesday morning -- after closing at $1.68 yesterday.

Ciphergen said yesterday morning that it had discovered two proteins that, in combination with PSA levels, may be useful within five years in the prediction of prostate cancer recurrence following surgery.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.